Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
ACS Pharmacology & Translational Science|February 17, 2023
Repurposing Ponatinib as a PD-L1 Inhibitor Revealed by Drug Repurposing Screening and Validation by <i>In Vitro</i> and <i>In Vivo</i> ExperimentsAnjali Barnwal, Sanjeev Das, Jayanta Bhattacharyya
ACS Applied Materials & Interfaces|April 17, 2023
Multifaceted Nano-DEV-IL for Sustained Release of IL-12 to Avert the Immunosuppressive Tumor Microenvironment and IL-12-Associated ToxicitiesAnjali Barnwal, Surajit Ganguly, Jayanta Bhattacharyya
British Journal of Cancer|July 3, 2023
Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expressionAnjali Barnwal, Rohini Tamang, Sanjeev Das, et al.
ACS Biomaterials Science & Engineering|October 23, 2023
Tumor Antigen-Primed Dendritic Cell-Derived Exosome Synergizes with Colony Stimulating Factor-1 Receptor Inhibitor by Modulating the Tumor Microenvironment and Systemic ImmunityAnjali Barnwal, Vidit Gaur, Anindita Sengupta, et al.
ACS Biomaterials Science & Engineering|November 29, 2022
SARS-CoV-2 Spike Protein-Activated Dendritic Cell-Derived Extracellular Vesicles Induce Antiviral Immunity in MiceAnjali Barnwal, Brohmomoy Basu, Aarti Tripathi, et al.
ACS Pharmacology & Translational Science|August 14, 2025
Ponatinib Averts αCD40 Antibody Mediated Toxicity by Lowering MAPK38 Expression and Shows Proimmunogenic Effects in a Murine Tumor ModelVidit Gaur, Anjali Barnwal, Khushboo Singh, et al.
Research Square|April 27, 2026
Anti-VEGF vascular remodeling drives germinal center B cell-rich tertiary lymphoid structures during antibody-toxin and anti-CD40 combination therapy in glioblastomaAnjali Barnwal, Weixuan Yan, Sarah Cook, et al.
Pageof 1